REL:LSE
RELX PLC
Data as of 2026-03-10 - not real-time
£2,646.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
RELX PLC trades at £26.46 (2646 p) just below its 50‑day SMA (≈£26.50) while holding a healthy RSI of 60 and a bullish MACD histogram, suggesting short‑term upside momentum despite a broader bearish trend. The stock’s trailing P/E of 23.6 sits well under the industry average of 29.5, and it delivers a solid 2.56% dividend yield with a payout ratio around 57%, indicating sustainable income. Analyst consensus is strongly positive – 15 analysts rate it a “strong buy” with median target £36.00, implying ~35% upside. Recent material news adds further catalyst: a £450 m non‑discretionary share buy‑back programme and an announced dividend increase to £0.48 per share, both likely to support price appreciation.
Risk considerations include high 30‑day volatility (~70%), a substantial net‑debt position (debt‑to‑equity >300%), and sector‑specific regulatory exposure, but the company’s low beta (≈0.28) and strong free cash flow generation mitigate market‑wide shocks.
Risk considerations include high 30‑day volatility (~70%), a substantial net‑debt position (debt‑to‑equity >300%), and sector‑specific regulatory exposure, but the company’s low beta (≈0.28) and strong free cash flow generation mitigate market‑wide shocks.
Trading Recommendations
Short Term
< 1 yearbuy
Conviction: 7/10
Key Factors
- Bullish MACD histogram despite bearish trend
- Upcoming dividend increase and £450 m buy‑back programme
- Price near resistance with upside potential to analyst targets
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- Strong analyst consensus and median price target above current level
- Attractive valuation relative to industry peers (lower P/E)
- Sustainable dividend yield and solid free cash flow
Long Term
> 3 yearsbuy
Conviction: 7/10
Key Factors
- Consistently high ROE and operating margins
- Diversified global revenue streams reducing geographic concentration
- Ongoing capital return initiatives (dividends and buy‑backs) supporting shareholder value
Key Metrics & Analysis
Financial Health
Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio23.6
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio2033.8
Op. Cash Flow£2.8B
Free Cash Flow£2.2B
Industry P/E29.5
Technical Analysis
TrendBearish
RSI60.2
Support£1,991.00
Resistance£2,679.00
MA 20£2,369.85
MA 50£2,650.42
MA 200£3,310.43
MACDBullish
VolumeStable
Fear & Greed Index75.89
Valuation
Fair Value£1,352.06
Target Price£3,733.00
Upside/Downside41.08%
GradeFair
TypeBlend
Dividend Yield2.56%
Risk Assessment
Beta0.28
Volatility69.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.